Detalhe da pesquisa
1.
Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I).
Lancet
; 401(10381): 1001-1010, 2023 03 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-36848918
2.
Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II).
Lancet
; 401(10381): 1011-1019, 2023 03 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-36848919
3.
Mechanism of action of baricitinib and identification of biomarkers and key immune pathways in patients with active systemic lupus erythematosus.
Ann Rheum Dis
; 2022 May 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-35609978
4.
Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial.
Lancet
; 392(10143): 222-231, 2018 07 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-30043749
5.
Clinical trial parameters that influence outcomes in lupus trials that use the systemic lupus erythematosus responder index.
Rheumatology (Oxford)
; 57(1): 125-133, 2018 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29045736
6.
JAK1/JAK2 inhibition by baricitinib in diabetic kidney disease: results from a Phase 2 randomized controlled clinical trial.
Nephrol Dial Transplant
; 33(11): 1950-1959, 2018 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29481660
7.
Safety profile of baricitinib in patients with systemic lupus erythematosus: an integrated analysis.
RMD Open
; 9(3)2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37604638
8.
Baricitinib decreases anti-dsDNA in patients with systemic lupus erythematosus: results from a phase II double-blind, randomized, placebo-controlled trial.
Arthritis Res Ther
; 24(1): 112, 2022 05 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-35578304
9.
Patient Experiences, Satisfaction, and Expectations with Current Systemic Lupus Erythematosus Treatment: Results of the SLE-UPDATE Survey.
Rheumatol Ther
; 8(3): 1189-1205, 2021 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-34164800
10.
Baricitinib-associated changes in global gene expression during a 24-week phase II clinical systemic lupus erythematosus trial implicates a mechanism of action through multiple immune-related pathways.
Lupus Sci Med
; 7(1)2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33037080
11.
JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies.
J Clin Invest
; 128(7): 3041-3052, 2018 07 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29649002